<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A five-agent GVHD prophylaxis programme consisting of <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, anti-thymocyte-globulin, pentaglobin and metronidazol was given to 48 recipients of unrelated donor marrow with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, and familiar lymphocytic <z:e sem="disease" ids="C0876991" disease_type="Disease or Syndrome" abbrv="">hemophagocytosis</z:e> of an average age of 33.5 (0.6-56) years </plain></SENT>
<SENT sid="1" pm="."><plain>GVHD grades II-IV occurred in 18 patients (39%) and grades III-IV in five patients (11%) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> GVHD developed in nine patients (23%), three limited and six extensive </plain></SENT>
<SENT sid="3" pm="."><plain>Fifteen patients died </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical relapse was detected in eight patients </plain></SENT>
<SENT sid="5" pm="."><plain>Four patients died as a consequence of the underlying disease and subsequent treatment, 11 patients died of transplant-related causes </plain></SENT>
<SENT sid="6" pm="."><plain>After a median follow-up of 19 months, the overall and disease-free survival are 67% and 62%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Survival by age is as follows: 0-19 years: 12/13 patients; 20-39 years: 14/25 patients; 40-59 years: 7/10 patients </plain></SENT>
<SENT sid="8" pm="."><plain>The five-agent GVHD prophylaxis regimen is effective </plain></SENT>
<SENT sid="9" pm="."><plain>Matched-unrelated donor transplants can be carried out safely in patients younger than 50 years of age </plain></SENT>
<SENT sid="10" pm="."><plain>The results in patients younger than 20 years of age should encourage matched-unrelated donor transplants at earlier stages of the disease </plain></SENT>
</text></document>